OmniActive’s (Morristown, NJ) CurcuWin ingredient, a highly bioavailable form of curcumin, has now obtained self-affirmed Generally Recognized as Safe (GRAS) status. The supplier announced on Friday that an expert panel had concluded its evaluation of the ingredient in accordance with FDA safety criteria, and arrived at a self-affirmed GRAS notification.
“OmniActive remains steadfast in delivering innovative, effective, and safe ingredients to the marketplace,” said Lynda M. Doyle, senior vice president of global marketing for OmniActive. “CurcuWin is a truly differentiated ingredient in the increasingly crowded enhanced curcumin market because our robust clinical program is showing how its higher bioavailability correlates to greater efficacy at a lower dose—what we’ve termed ‘bioavailability with a purpose.’ And now, by gaining GRAS self-affirmation, CurcuWin sets itself apart yet again.”
CurcuWin, which is produced through OmniActive’s proprietary UltraSol technology, was also found to enhance vascular function by improving flow-mediated dilation in a recent study.